Mahesh Radhakrishnan
Overview
Explore the profile of Mahesh Radhakrishnan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
217
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gupta D, Prabhakar V, Radhakrishnan M
Neurosci Biobehav Rev
. 2016 Mar;
64:311-25.
PMID: 26976353
5HT3 receptors (5HT3Rs) have long been identified as a potential target for antidepressants. Several studies have reported that antagonism of 5HT3Rs produces antidepressant-like effects. However, the exact role of 5HT3Rs...
2.
Gupta D, Thangaraj D, Radhakrishnan M
Behav Brain Res
. 2015 Oct;
297:41-50.
PMID: 26454237
Despite the presence of a multitudinous pharmacotherapy, diabetes-induced depressive disorder remains undertreated. Evidence suggests that brain serotonergic deficits are associated with depressive-like behavior in diabetes and that 5HT3 receptor (5HT3R)...
3.
Gupta D, Radhakrishnan M, Thangaraj D, Kurhe Y
J Pharm Bioallied Sci
. 2015 Apr;
7(2):103-8.
PMID: 25883513
Objective: In the last few decades, serotonin type-3 (5-HT3) receptor antagonists have been identified as potential targets for anxiety disorders. In preclinical studies, 5-HT3 antagonists have shown promising antianxiety effects....
4.
Prabhakar V, Gupta D, Kanade P, Radhakrishnan M
Indian J Pharmacol
. 2015 Mar;
47(1):4-10.
PMID: 25821303
Diabetes associated depression is a largely understudied field which nonetheless carries a significant disease burden. The very low therapeutic efficacy of the existing conventional drugs with poor outcome may be,...
5.
Gupta D, Radhakrishnan M, Kurhe Y
Steroids
. 2015 Feb;
96:95-102.
PMID: 25668613
Stress in our daily life severely affects the normal physiology of the biological system. Dysregulation of hypothalamic-pituitary-adrenal (HPA) axis has been implicated in the development of depression-like behavior, which remains...
6.
Gupta D, Radhakrishnan M, Kurhe Y, Thangaraj D, Prabhakar V, Kanade P
Acta Pharmacol Sin
. 2014 Nov;
35(12):1493-503.
PMID: 25418380
Aim: To investigate the antidepressant-like effects of a novel 5-HT3 receptor antagonist N-(benzo[d]thiazol-2-yl)-3-methoxyquinoxalin-2-carboxamide (6z) in acute and chronic murine models of depression. Methods: 5-HT3 receptor antagonism was examined in guinea...
7.
Gupta D, Radhakrishnan M, Kurhe Y
Eur J Pharmacol
. 2014 Oct;
744:59-66.
PMID: 25284215
Increased prevalence and high comorbidity of depression-like mood disorders and diabetes have prompted investigation of new targets and potential contributing agents. There is considerable evidence supporting the inconsistent clinical efficacy...
8.
Gupta D, Radhakrishnan M, Kurhe Y
Eur J Pharmacol
. 2014 Sep;
742:94-101.
PMID: 25199966
Anxiety disorders are widely spread psychiatric illnesses that are a cause of major concern. Despite a consistent increase in anxiolytics, the prevalence of anxiety is static; this necessitates the development...
9.
Kurhe Y, Radhakrishnan M, Gupta D
Metab Brain Dis
. 2014 Jun;
29(3):701-10.
PMID: 24964970
The aim of the present work was to investigate the role of ondansetron on the high fat diet (HFD) induced obese mice for behavioral and biochemical alterations using chronic unpredictable...
10.
Gupta D, Radhakrishnan M, Kurhe Y
Pharmacol Biochem Behav
. 2014 Jun;
124:129-36.
PMID: 24909071
Chronic stress is one of the major causes of depression, associated with behavioral and biochemical impairments. 5HT3 receptor antagonists (such as ondansetron) have shown alleviation of depressive symptomology in preclinical...